Novo Nordisk, United Biotechnology Report 19.7% Weight Loss in New Study

Novo Nordisk, the Danish pharmaceutical giant known for diabetes and obesity treatments, announced impressive new clinical trial results in collaboration with United Biotechnology for an experimental obesity drug called UBT251. The mid‑stage trial reported a mean weight loss of up to 19.7% after 24 weeks, significantly outperforming the placebo group, which saw just 2.0% weight loss over the same period. This outcome underscores the potential of the drug to become a new tool against obesity worldwide.